

ASX RELEASE

CARDIOCEL® SHOWS NO EVIDENCE OF CALCIFICATION AFTER 7 YEARS IN LONG TERM FOLLOW-UP TO PHASE II TRIAL

- 11 patients have now had a CardioCel® Adapted Collagen Scaffold implanted for over five years; one patient for over 7 years
- All patients are progressing well
- No repeat procedures have been required

Brisbane, Australia 8th July, 2015

Admedus Limited (ASX:AHZ) today announced positive long-term data from the CardioCel® Phase II clinical trial assessing the efficacy and safety of the Company's proprietary bio-scaffold which has been implanted to repair congenital heart disease defects.

Importantly, there have been no repeat heart procedures related to CardioCel® for the monitored patients in the study and there are no signs of CardioCel® calcification. In this trial, 11 patients have now had CardioCel® implanted for over five years with one patient being implanted with the device over seven years ago. The current status of patients is:

- A total of 11 patients are now past 5 years post implantation including:
 - One patient over 7 years post implantation
 - Four patients over 6 years post implantation
 - Six patients over 5 years post implantation
- Admedus is also following another 4 patients who are past 4 years post implantation.

Mr Lee Rodne, CEO of Admedus commented "This long-term follow-up data illustrates some of the key features of CardioCel® that we believe make it the bio-scaffold of choice for the repair of congenital heart disease defects. Given that the first patient in this Phase II clinical trial was treated over seven years ago and the patient is doing very well, we are particularly encouraged that there has been no requirement for repeat procedures and no evidence of calcification of the implanted device."

Admedus and the participating hospital will continue to follow a number of patients from the Phase II study through this extended program.

"These results are very exciting given the fact that CardioCel® show no signs of calcification after 5 plus years, especially since it is known that other tissues implanted in children tends to calcify rapidly, thus proving the effectiveness of the ADAPT® tissue engineering process to produce bio-scaffold implantable tissue products like CardioCel®. These are very important data as we expand the use of CardioCel® into the adult cardiac and the peripheral vascular markets." Said Professor Leon Neethling, inventor of the ADAPT® technology and CardioCel®.

CardioCel® is currently used in over 90 centers globally and 42 are based in the US, demonstrating a high level of adoption within the first 12 months within the market.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 3 9620 5454

Media:

Haley Price

+61 (0) 423 139 163

hprice@admedus.com

Media Europe & Asia

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

About CardioCel®

CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects.

It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

CardioCel® is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group's proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.